ABSTRACT
It is well known fact that diabetics are prone to develop infections and have increased mortality and morbidity than non-diabetics. However, the effect of diabetes mellitus on the risk of pneumonia remains uncertain. We wanted to study the aetiology, clinical features, and the outcome of pneumonia in diabetic patients. METHODSA comparative observational study was conducted in a tertiary care hospital, southern India which included 50 diabetic patients with pneumonia and 50 non-diabetic patients with pneumonia. Clinical characteristics, x-ray findings, aetiological agents, and outcome of diabetic patients were analysed and compared with data from the control group. RESULTSDiabetic patients with pneumonia were more unwell at the time of admission in the form of high PSI (Pneumonia Severity Index) score (p = 0.004**), intensive care admissions and prolonged hospital stay (p = < 0.001**). Diabetic patients were significantly associated with multilobar involvement (p = 0.045*). There was no significant difference in age, gender, coexisting underlying disease and complications. In patients with diabetes mellitus, mortality was associated with multilobar infiltrate, increased PSI score (p = 0.078*) at admission. CONCLUSIONSThese is a significant difference between pneumonia in diabetics compared with non-diabetics. Diabetic patients had presented with higher PSI score, required more ICU admissions and had prolonged hospitalization. Diabetes is also associated with bad prognosis and high mortality.
ABSTRACT
Tonsillopharyngitis is very common in children, with Group A Streptococci being the most common bacterial etiology. Effective antibacterial treatment is imperative due to risk of rheumatic fever. Cephalosporins have been used successfully for the treatment of Group A beta-hemolytic Streptococcal (GABHS) tonsillopharyngitis. Cefprozil is a novel broad-spectrum oral cephalosporin. Cefprozil is rapidly absorbed from the gastrointestinal tract with high bioavailability. The excellent penetration of cefprozil into tonsillar and adenoidal tissue corresponds well with the clinical outcome. The drug provides excellent coverage against both gram-negative and -positive bacteria that may cause pharyngitis/tonsillitis. The beta-lactamase stability of cefprozil appears to exceed that of other oral cephalosporins for important gram negative pathogens. In clinical trials, cefprozil appears to be at least as effective as commonly used comparison agents such as cefaclor and cefixime. Additionally, cefprozil is better tolerated than the latter, especially with regard to gastrointestinal adverse effects. Thus cefprozil can be considered a safe and reliable drug for the treatment of Streptococcal tonsillopharyngitis in children.